Media headlines about Bioverativ (NASDAQ:BIVV) have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bioverativ earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.6984634178866 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Bioverativ (NASDAQ BIVV) traded up $0.43 during mid-day trading on Wednesday, hitting $50.68. 782,429 shares of the stock were exchanged, compared to its average volume of 1,605,192. Bioverativ has a 52-week low of $40.00 and a 52-week high of $64.41.
Bioverativ (NASDAQ:BIVV) last issued its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.25. The business had revenue of $291.60 million during the quarter, compared to analyst estimates of $285.45 million. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The company’s revenue for the quarter was up 27.2% on a year-over-year basis. equities research analysts forecast that Bioverativ will post 2.45 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Bioverativ (BIVV) Stock Price” was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/12/06/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-bioverativ-bivv-stock-price.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.